Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: DENND2C

Gene summary for DENND2C

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

DENND2C

Gene ID

163259

Gene nameDENN domain containing 2C
Gene AliasdJ1156J9.1
Cytomap1p13.2
Gene Typeprotein-coding
GO ID

GO:0008150

UniProtAcc

Q68D51


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
163259DENND2CC43HumanOral cavityOSCC1.66e-021.27e-010.1704
163259DENND2CC57HumanOral cavityOSCC1.49e-299.62e-010.1679
163259DENND2CC09HumanOral cavityOSCC9.53e-241.21e+000.1431
163259DENND2CLN22HumanOral cavityOSCC1.13e-061.20e+000.1733
163259DENND2CLN46HumanOral cavityOSCC3.32e-024.31e-010.1666
163259DENND2CLP15HumanOral cavityLP1.51e-027.98e-010.2174
163259DENND2CSYSMH1HumanOral cavityOSCC2.83e-103.56e-010.1127
163259DENND2CSYSMH2HumanOral cavityOSCC2.86e-104.42e-010.2326
163259DENND2CSYSMH3HumanOral cavityOSCC2.19e-135.21e-010.2442
163259DENND2CP1_S1_AKHumanSkinAK5.03e-327.23e-01-0.3399
163259DENND2CP2_S3_AKHumanSkinAK7.86e-256.15e-01-0.3287
163259DENND2CP2_S4_SCCISHumanSkinSCCIS5.12e-175.49e-01-0.3043
163259DENND2CP3_S6_AKHumanSkinAK3.17e-104.82e-01-0.3256
163259DENND2CP4_S8_cSCCHumanSkincSCC5.49e-184.92e-01-0.3095
163259DENND2CP5_S10_cSCCHumanSkincSCC4.06e-376.66e-01-0.299
163259DENND2CP1_cSCCHumanSkincSCC2.33e-052.54e-010.0292
163259DENND2CP4_cSCCHumanSkincSCC1.81e-063.30e-01-0.00290000000000005
163259DENND2CP10_cSCCHumanSkincSCC9.36e-084.05e-010.1017
163259DENND2CcSCC_p8HumanSkincSCC5.18e-031.33e-01-0.1971
Page: 1 2 3 4 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
CervixThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.CC: Cervix cancer
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
N_HPV: HPV-infected normal cervix
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
Page: 1 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
DENND2CSNVMissense_Mutationnovelc.824N>Cp.Glu275Alap.E275AQ68D51protein_codingdeleterious(0)probably_damaging(0.998)TCGA-A7-A6VX-01Breastbreast invasive carcinomaFemale>=65I/IIChemotherapydocetaxelCR
DENND2CSNVMissense_Mutationc.80N>Tp.Gln27Leup.Q27LQ68D51protein_codingdeleterious(0.02)benign(0.297)TCGA-AN-A0FW-01Breastbreast invasive carcinomaFemale>=65III/IVUnknownUnknownSD
DENND2CSNVMissense_Mutationc.2501N>Gp.Ser834Cysp.S834CQ68D51protein_codingdeleterious(0)probably_damaging(0.998)TCGA-AR-A250-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapydoxorubicinSD
DENND2CSNVMissense_Mutationnovelc.397N>Cp.Asp133Hisp.D133HQ68D51protein_codingdeleterious(0.03)benign(0.003)TCGA-E2-A2P6-01Breastbreast invasive carcinomaFemale>=65I/IIHormone TherapyanastrozoleSD
DENND2CSNVMissense_Mutationc.2398N>Cp.Glu800Glnp.E800QQ68D51protein_codingdeleterious(0.01)possibly_damaging(0.776)TCGA-GM-A2D9-01Breastbreast invasive carcinomaFemale>=65I/IIHormone TherapyarimidexSD
DENND2CdeletionFrame_Shift_Delnovelc.2077delAp.Arg693GlyfsTer2p.R693Gfs*2Q68D51protein_codingTCGA-D8-A27V-01Breastbreast invasive carcinomaFemale<65I/IIHormone TherapytamoxiphenSD
DENND2CSNVMissense_Mutationnovelc.916G>Ap.Glu306Lysp.E306KQ68D51protein_codingdeleterious(0.01)probably_damaging(0.955)TCGA-C5-A1M7-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
DENND2CSNVMissense_Mutationrs772944552c.310N>Ap.Asp104Asnp.D104NQ68D51protein_codingtolerated(0.34)benign(0.001)TCGA-C5-A1ME-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
DENND2CSNVMissense_Mutationc.193G>Ap.Glu65Lysp.E65KQ68D51protein_codingtolerated(0.4)benign(0.013)TCGA-C5-A3HE-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownPD
DENND2CSNVMissense_Mutationrs746690091c.1988N>Ap.Arg663Glnp.R663QQ68D51protein_codingdeleterious(0)probably_damaging(0.999)TCGA-DS-A1OD-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinSD
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1